The 2026 Aging Research and Drug Discovery meeting at Harvard Medical School marked a shift from scientific presentation toward regulatory and commercial alignment, with FDA officials outlining what an approvable aging indication would require and ARPA-H detailing its $144m PROSPR program to build validated trial infrastructure. Novo Nordisk presented SELECT-based modelling projecting 1.9 additional years of life on semaglutide, while Eli Lilly reported that all 15 epigenetic clocks measured in a SURMOUNT-5 sub-study showed less biological aging than the 1.38 calendar years elapsed on tirzepatide. Large pharmaceutical developers are now running biological-age readouts as formal endpoints rather than exploratory curiosities.
Key Points
- FDA expects first approvable trials targeting age-related comorbidity or mortality prevention
- Tirzepatide sub-study: 15 epigenetic clocks showed aging slower than calendar time
- ARPA-H's $144m PROSPR program building regulator-accepted surrogate endpoint infrastructure
Longevity Analysis
The central obstacle in aging therapeutics has never been candidate molecules but measurement — the absence of surrogate endpoints regulators will accept shorter than mortality itself. Defining a population with decline across cognition, frailty, hearing and vision, then tracking intrinsic capacity alongside hard outcomes, is an attempt to make the body's rate of deterioration legible to a regulatory system built around single-disease endpoints. For practitioners, the epigenetic findings on metabolic agents suggest that interventions targeting energy regulation and inflammatory load produce measurable effects on regeneration and repair capacity, though the link between clock movement and survival remains unproven.
Original published by Longevity.Technology, by Phil Newman.